Astellas Pharma Inc. rose the most in more than three months after quarterly profit exceeded analysts’ projections, driven by ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Astellas has reached Phase 1 testing with ASP3082, an internally developed drug candidate designed to degrade a cancer target called KRAS G12D. Mutated versions of this protein are found in ...

Astellas Pharma Inc. (ALPMY) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in ...

Here’s part 2 of MedCity News’ Q&A with Astellas Pharma CEO Naoki Okamura, who was in South San Francisco last week for the opening of the Japanese pharma company’s West Coast Innovation Center.

The Astellas Pharma executive was sentenced to 3½ years in a case that has added strain to relations between Tokyo and Beijing.

Astellas Pharma (ALPMY) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions ...

Photo: Akio Kon/Bloomberg News Astellas Pharma Inc. said Monday that it agreed to acquire Iveric bio Inc. for about $5.9 billion to strengthen its capabilities in the ophthalmology field.

Astellas Pharma Inc., based in Tokyo, announced July 11 that it completed its previously announced $5.9 billion acquisition of Iveric Bio Inc., an early-stage biopharmaceutical company based in ...

Astellas Pharma Inc ALPMF ALPMY decided to license and advance a gene therapy from Kate Therapeutics for a debilitating muscle disorder known as X-linked myotubular myopathy (XLMTM). Preclinical ...

While it remains to be seen if pop superstar Taylor Swift will attend Super Bowl LVIII, we know Astellas Pharma will be there. The Japanese drugmaker announced Thursday morning that it will run a ...

Astellas Pharma (ALPMY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).